ストックスクリーナーアプリを入手
2.10
0.48%
0.01
Dare Bioscience Inc (DARE) 最新ニュース
Daré Bioscience enters into $15M stock purchase agreement - MSN
Dare Bioscience risks Nasdaq delisting over market value - MSN
DARE Secures Gates Foundation Funding for Preeclampsia Projects - GuruFocus
Daré Bioscience, Inc. Secures $499,000 Grant from Gates Foundation to Address Preeclampsia in Women's Health - Quiver Quantitative
Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research - GlobeNewswire
76,000 Maternal Deaths Annually: Daré Bioscience Receives Gates Grant to Combat Preeclampsia Crisis - Stock Titan
Dare Bioscience (NASDAQ:DARE) Shares Pass Below 200 Day Moving Average – What’s Next? - Defense World
Daré Bioscience targets Q4 2025 launch for DARE to PLAY Sildenafil cream while advancing dual-path strategy - MSN
What’s the recovery path for long term holders of Daré Bioscience Inc.Inflation Watch & Low Drawdown Investment Ideas - newser.com
Using Python tools to backtest Daré Bioscience Inc. strategies2025 Price Action Summary & Comprehensive Market Scan Insights - Newser
Maxim upgrades Daré Bioscience on extended cash runway, commercial launch - TradingView
Maxim Group upgrades Dare Bioscience stock to Buy on funding boost - Investing.com Canada
Dare Bioscience (DARE) Upgraded to Buy by Maxim Group | DARE Sto - GuruFocus
Dare Bioscience shares rise 4.37% premarket after Maxim upgraded to Buy from Hold. - AInvest
Dare Bioscience: Maxim Group upgrades Buy from Hold, PT $8. - AInvest
Maxim Upgrades Dare Bioscience to Buy From Hold, Price Target is $8 - MarketScreener
This Brinker International Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Benzinga
Daré Bioscience Engages Market with New Presentation - TipRanks
Daré Bioscience, Inc. (NASDAQ:DARE) Q2 2025 Earnings Call Transcript - MSN
Pattern recognition hints at Daré Bioscience Inc. upsideQuarterly Trade Review & Long-Term Safe Investment Ideas - Newser
Brookline Capital Markets Sticks to Their Buy Rating for Daré Bioscience (DARE) - The Globe and Mail
Dolliver Maintains Buy Rating on Daré Bioscience with $11 Price Target - AInvest
Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Lags Revenue Estimates - MSN
Dare Bioscience stock price target lowered to $11 at Brookline Capital - Investing.com Canada
Daré Bioscience's Strategic Growth and Market Expansion Ahead of Sildenafil Cream Launch - AInvest
Daré Bioscience: Strategic Growth and Market Expansion with Upcoming Sildenafil Cream Launch - TipRanks
Dare Bioscience shares fall 3.55% after-hours following Q2 2025 earnings call. - AInvest
Dare Bioscience 2025 Q2 Earnings Net Loss Widens Sharply - AInvest
Dare Bioscience 2025 Q2 Earnings Sharp Net Loss Deteriorates 131% - AInvest
Dare Bioscience Inc (DARE) Q2 2025 Earnings Call Highlights: Strategic Advances and Financial ... - Yahoo Finance
Daré Bioscience Announces Q2 2025 Financial Results - TipRanks
Daré Bioscience Q2 2025 Earnings Call: Financial Results and Business Update - AInvest
Daré Bioscience's Q2 2025: Diverging Paths in Marketing, Financial Health, and R&D Investment - AInvest
Daré Bioscience's Q2 2025 Earnings: A Strategic Inflection Point in Women's Health Innovation - AInvest
Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Earnings call transcript: Dare Bioscience Q2 2025 reports cash boost, product updates - Investing.com Canada
Transcript : Daré Bioscience, Inc., Q2 2025 Earnings Call, Aug 14, 2025 - MarketScreener
Daré Bioscience Posts Narrower Q2 Loss - The Motley Fool
Daré Bioscience Readies First Commercial Product Launch as Multiple Women's Health Solutions Near Market - Stock Titan
Dare Bioscience Inc expected to post a loss of 58 cents a shareEarnings Preview - TradingView
Dare Bioscience (DARE) down more than 70% since Jul 14 - AInvest
Daré Bioscience to Host Second Quarter 2025 Financial - GlobeNewswire
Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025 - The Manila Times
Daré Bioscience to Present Q2 Results: Women's Health Pipeline and Financial Updates Coming August 14 - Stock Titan
Dare Bioscience shares fall 1.61% premarket after launching consumer awareness campaign for DARE to PLAY Sildenafil Cream. - AInvest
Dare Bioscience shares fall 2.75% intraday after launching consumer awareness campaign for DARE to PLAY Sildenafil Cream. - AInvest
Daré Bioscience and Rosy Wellness Launch First Phase of - GlobeNewswire
Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream - The Manila Times
2.36%
1.10%
大文字化:
|
ボリューム (24 時間):